ATP8B2 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-57018
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Synthetic peptides corresponding to ATP8B2 (ATPase, class I, type 8B, member 2) The peptide sequence was selected from the N terminal of ATP8B2.
Peptide sequence MAVCAKKRPPEEERRARANDREYNEKFQYASNCIKTSKYNILTFLPVNLF. The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Scientific Data Images for ATP8B2 Antibody
Western Blot: ATP8B2 Antibody [NBP1-57018]
Western Blot: ATP8B2 Antibody [NBP1-57018] - Jurkat cell lysate, concentration 0.2-1 ug/ml.Applications for ATP8B2 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: ATP8B2
Alternate Names
ATPase, class I, type 8B, member 2, ATPIDprobable phospholipid-transporting ATPase ID, DKFZp434M0219, EC 3.6.3, EC 3.6.3.1, KIAA1137ATPase class I type 8B member 2, phospholipid-transporting ATPase ID
Gene Symbol
ATP8B2
Additional ATP8B2 Products
Product Documents for ATP8B2 Antibody
Product Specific Notices for ATP8B2 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...